Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Worries Over Blockbuster Meds Avandia, Fosamax


Related Encyclopedia
 border=
Addison's Disease
Alzheimer's Disease
Aneurysms
Angina Pectoris
More...

Related Healthscout Videos
 border=
Importance of Good Nutrition
Nature’s Remedies
Controlling Incontinence
Preventing Heart Disease the Easy Way
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Coronary Bypass Surgery
Diabetes
More...

Related Drug Information
 border=
Accupril
Actonel
Actos
Altace
More...

Related News Articles
 border=
It's a Whole New Outlook for Cataract Patients
Study Questions Guidelines on Immunizations
Could Chinese Herb Be a Natural Viagra?
Gestational Diabetes Risk Higher for Asian-White Couples
More...


Page:  << Prev | 1 | 2 | 3 | Next >>

Other anti-diabetic drugs did not show the same effect, but thiazolidinediones have a different mechanism of action (working at the cellular level) than other drugs for type 2 diabetes.

The findings echo some previous research which found an increased risk of fractures in women.

For now, the decision to use these particular diabetes drugs should be made on a case-by-case basis, experts said. Women who are postmenopausal and therefore at risk for fractures may want to be more careful, or take other measures to protect their bone health, they said.

Text Continues Below



"I think the benefit is more than the risk at this point. The benefit is huge in terms of glycemic control," said Dr. Spyros G.E. Mezitis, endocrinology consultant and clinical investigator at Lenox Hill Hospital in New York City.

"It remains to be seen if the way we practice medicine is going to change. These are important analyses, but we need further evidence," Mezitis added.

Nancy Pekarek, a spokeswoman for Avandia manufacturer GlaxoSmithKline, noted, "We do have fractures on our label and, in fact, when we saw data from the ADOPT (a previous, long-term trial), we issued a 'dear doctor' letter."

"The fractures have been observed, and we have made physicians aware of that so they can be watching for their patients and choose which drug is appropriate," Pekarek said. Unlike this trial, the fractures seen in ADOPT were more likely to be in the upper arm, hand or foot as opposed to hip and spine.

The Fosamax study, led by Dr. Susan Heckbert of the University of Washington and Group Health, Seattle, looked at 719 women with confirmed atrial fibrillation in a "real world" setting, versus 966 controls (without atrial fibrillation).

The study found that 6.5 percent of women who had used Fosamax had atrial fibrillation compared to 4.1 percent of controls. Based on these findings, the researchers estimated that 3 percent of new cases of atrial fibrillation in this group of women might be attributable to the use of Fosamax.

Page:  << Prev | 1 | 2 | 3 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/28/2008

Related Links
 border=
From Healthscout's partner site on heart disease, MyHeartCentral.com
Learn about heart disease symptoms.
Get more information on heart disease treatment for your health!
What can you do to prevent heart disease? Prevention details here.





SOURCES: Spyros G.E. Mezitis, M.D., Ph.D., endocrinology consultant and clinical investigator at Lenox Hill Hospital, and clinical assistant professor of medicine, NewYork-Presbyterian Hospital/Cornell Medical Center, New York City; Nancy Pekarek, spokeswoman, GlaxoSmithKline; Ronald Rogers, spokesman, Merck & Co. Inc.; April 28, 2008, Archives of Internal Medicine; March 11, 2008, British Medical Journal


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map